CINECA IRIS Institutional Research Information System

SANGIOLO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.145
EU - Europa 3.620
AS - Asia 2.795
SA - Sud America 297
AF - Africa 46
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 9
Totale 12.953
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.765
CN - Cina 1.129
IT - Italia 1.089
SG - Singapore 759
DE - Germania 697
GB - Regno Unito 350
CA - Canada 344
IE - Irlanda 297
SE - Svezia 258
BR - Brasile 246
TR - Turchia 205
FI - Finlandia 187
FR - Francia 176
VN - Vietnam 122
JP - Giappone 115
PL - Polonia 94
UA - Ucraina 94
KR - Corea 92
IN - India 76
HK - Hong Kong 72
ES - Italia 64
NL - Olanda 64
ID - Indonesia 54
TW - Taiwan 52
AT - Austria 44
AU - Australia 35
BE - Belgio 34
RU - Federazione Russa 34
CH - Svizzera 27
MX - Messico 25
TH - Thailandia 25
NO - Norvegia 24
AR - Argentina 19
PT - Portogallo 17
IR - Iran 16
SN - Senegal 14
SA - Arabia Saudita 13
IL - Israele 12
GR - Grecia 11
RO - Romania 11
VE - Venezuela 11
HR - Croazia 9
ZA - Sudafrica 8
EG - Egitto 7
EU - Europa 7
UZ - Uzbekistan 7
CO - Colombia 6
HU - Ungheria 6
KE - Kenya 6
NZ - Nuova Zelanda 6
PK - Pakistan 6
AE - Emirati Arabi Uniti 5
BY - Bielorussia 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
IQ - Iraq 5
LT - Lituania 5
AM - Armenia 4
CL - Cile 4
DK - Danimarca 4
BA - Bosnia-Erzegovina 3
BD - Bangladesh 3
JM - Giamaica 3
JO - Giordania 3
MK - Macedonia 3
MY - Malesia 3
NG - Nigeria 3
PA - Panama 3
PE - Perù 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
DZ - Algeria 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
MA - Marocco 2
NP - Nepal 2
PH - Filippine 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BT - Bhutan 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
KG - Kirghizistan 1
LK - Sri Lanka 1
OM - Oman 1
PR - Porto Rico 1
SI - Slovenia 1
SV - El Salvador 1
TG - Togo 1
Totale 12.953
Salva come PNG Salva come JPEG
Città #
Chandler 523
Singapore 424
Fairfield 406
Beijing 391
Munich 388
Houston 342
Dublin 292
Mcallen 278
Ashburn 276
Montréal 273
Santa Clara 266
Torino 201
Turin 198
Woodbridge 198
Ann Arbor 182
Seattle 171
Wilmington 146
Jacksonville 135
Nyköping 121
Cambridge 116
Shanghai 106
Pisa 100
Columbus 97
New York 94
Redwood City 94
Medford 89
Dearborn 79
Villeurbanne 78
Princeton 77
Warsaw 74
Milan 72
Guangzhou 69
Dong Ket 55
The Dalles 54
Jakarta 53
Nanjing 51
Helsinki 47
Hefei 44
Hong Kong 42
Fremont 40
Boston 39
San Diego 38
Taipei 38
Turku 36
Boardman 34
Los Angeles 34
Hangzhou 32
Nuremberg 29
Wuhan 26
Chicago 25
Silver Spring 25
Xian 24
Washington 23
Tokyo 22
Vienna 22
Brussels 19
Rome 19
Seoul 19
São Paulo 19
Toronto 19
Pune 18
Zhengzhou 18
Chengdu 16
Dresden 16
Hebei 16
Istanbul 16
Phoenix 16
Berlin 15
Düsseldorf 15
Changsha 14
Kunming 14
Madrid 14
Upper Marlboro 14
Dallas 13
Frankfurt am Main 13
Stavanger 13
Belo Horizonte 12
Bologna 12
Lappeenranta 12
Lauterbourg 12
Paris 12
San Francisco 12
Tianjin 12
Florence 11
Norwalk 11
San Mateo 11
Carrara 10
Changchun 10
Freiburg im Breisgau 10
Fuzhou 10
Jinan 10
Montreal 10
Porto Alegre 10
Sydney 10
Ankara 9
Bangkok 9
Barcelona 9
Bari 9
Birmingham 9
Buenos Aires 9
Totale 7.776
Salva come PNG Salva come JPEG
Nome #
Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. 1.405
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial 1.064
Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity? 549
Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 446
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group 423
Cytokine Induced Killer cells kill chemo-surviving melanoma cancer stem cells 345
Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. 259
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody 256
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models 228
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition 227
Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. 224
Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 198
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma 183
Adoptive immunotherapy against ovarian cancer 182
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 172
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. 171
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 167
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy 166
Pazopanib and trametinib as a synergistic strategy against osteosarcoma: Preclinical activity and molecular insights 163
Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 160
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives 154
Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. 153
Abstract LB-366: Everolimus (EV) potentiates Sorafenib (SOR)activity in osteosarcoma (OS) preclinical models: a combination targeting the crosstalk between ERK1/2 and mTORC1/2 signaling pathways 152
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. 148
DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination 147
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 145
CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy 145
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer 145
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 141
Next generation immune-checkpoints for cancer therapy 127
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors 125
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 123
Recent advances in the development of breast cancer vaccines. 117
Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models 117
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. 116
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 112
Cytokine Induced Killer cells immunotherapy overcomes the resistance to MET tyrosine kinase inhibitors in nonsmall cell lung cancer 111
Efficient transcriptional targeting of human hematopoietic stem cells and blood cell lineages by lentiviral vectors containing the regulatory element of the Wiskott-Aldrich Syndrome gene 105
Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. 105
Treatment of metastatic melanoma: a multidisciplinary approach 105
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 104
Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells 102
Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective 100
Adoptive immunotherapy against sarcomas. 99
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. 95
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES 93
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation 92
Comparison of post-transplant events and outcomes in patients affected by haematological or solid malignancies undergone to a non-myeloablative allogeneic haematopoietic stem cell transplantation in progressive disease 91
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 88
Epha2 expression in bone sarcomas: Bioinformatic analyses and preclinical characterization in patient-derived models of osteosarcoma, ewing’s sarcoma and chondrosarcoma 88
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 87
Cytokine-induced killer cells as immunotherapy for solid tumors: current evidences and perspectives 86
Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour 85
Effective Activity of Cytokine Induced Killer Cells against Autologous Metastatic Melanoma including Cells with Stemness Features. 85
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 84
Cytokine-Induced Killer (CIK) Cells from Colorectal Cancer Patients after Nonmyeloablative Hematopoietic Cell Transplantation: Tumor Killing Capacity and Alloreactivity across MHC Barriers 84
Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD 83
Cytokine profiling of end stage cancer patients treated with immunotherapy 83
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features 80
Parp1 inhibitor and trabectedin combination does not increase tumor mutational burden in advanced sarcomas—a preclinical and translational study 79
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages 78
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. 77
Veliparib: a new therapeutic option in ovarian cancer? 76
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 75
Delving into PARP inhibition from bench to bedside and back 73
Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST 71
Alloreactivity and antitumor activity segregate within two distinct subsets of Cytokine-Induced Killer Cells: Implications for their infusion Across major HLA-barriers. 70
The Combination of Sorafenib and Everolimus abrogates mTORC-1 and mTORC2 up-regulation in preclinical models of Osteosarcoma. 69
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 66
The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies 65
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 61
Sequential Lentiviral Transduction Conferring Simultaneous Sensitivity to Ganciclovir and Resistance to Mycophenolate Mofetil 60
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study 59
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 55
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 54
Outcome of allogeneic hematopoietic cell transplantation (HCT) for patients with severe aplastic anemkia (SAA) above the age of 40 years 54
Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19 53
Role of interferon in melanoma: old hopes and new perspectives 53
Treating breast cancer with cell-based approaches: an overview 51
Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow 50
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 48
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis 44
Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade 42
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 40
Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. 40
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 39
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective 38
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 38
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study 38
MET Oncogene Targeting for Cancer Immunotherapy 37
Redirecting GVT after Allografting in Colorectal Cancer: Active Vaccination and Adoptive Immunotherapy 37
Redirectedt cells in cancer therapy 34
Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model 30
Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets 30
Cytokine induced killer cells as promising immunotherapy for solid tumors 29
Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy 28
Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection 25
Significance of TIM3 expression in cancer: From biology to the clinic 22
Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial 20
Totale 13.298
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.061
article - articoli 0
book - libri 0
conference - conferenze 3.544
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.605
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.305 84 125 89 114 98 86 76 80 110 132 110 201
2021/20221.235 69 91 48 74 73 47 86 74 60 111 279 223
2022/20231.779 126 171 42 174 129 400 148 127 216 53 123 70
2023/20241.074 109 158 74 84 62 161 56 59 11 75 101 124
2024/20252.574 57 161 156 223 462 204 90 163 255 211 244 348
2025/2026170 170 0 0 0 0 0 0 0 0 0 0 0
Totale 13.298